Q2 FY2026 · ended Jun 30, 2026 · Revenue $33,000, +450.0% YoY · Filed Aug 13, 2026
PAVmed Inc. (PAVM) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $33,000 and a net loss of $5.4 million. Free cash flow was -$2.7 million. As of Jun 30, 2026 it held $3.8 million in cash and investments and $2.0 million in total debt.
Revenue
$33,000
+450.0% vs year-ago quarter
Net income
$-5.38M
+54.8% vs year-ago quarter
Operating cash flow
$-2.66M
-126.1% vs year-ago quarter
Free cash flow
$-2.68M
-125.6% vs year-ago quarter
EPS
$-0.87
+96.1% vs year-ago quarter
Dividend per share
None
Shares outstanding
8.00M
+9.9% vs prior quarter
Net cash
$1.82M
Q2 FY2026
Operating margin
-23842.0%
TTM
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- PAVM (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1624326
- Former names
- PAXmed Inc. (until Mar 26, 2015)
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $33,000 | $22,000 | $52,000 | $5,000 | $6,000 |
| Operating income | -$7.0M | -$8.0M | -$6.8M | -$4.8M | -$4.7M |
| Net income | -$5.4M | -$60,000 | -$1.3M | -$5.4M | -$11.9M |
| Diluted EPS | -$0.87 | -$4.42 | $0.04 | -$0.29 | -$22.08 |
| Operating cash flow | -$2.7M | -$2.6M | -$1.6M | -$896,000 | -$1.2M |
| Free cash flow | -$2.7M | -$2.6M | -$1.6M | -$899,000 | -$1.2M |
| Total assets | $40.2M | $45.4M | $38.8M | $38.1M | $43.9M |
| Total liabilities | $20.9M | $20.4M | $16.5M | $12.3M | $12.5M |
| Stockholders' equity | $35.0M | $39.5M | $34.0M | $32.5M | $37.5M |
| Cash and investments | $3.8M | $6.5M | $1.5M | — | — |
| Total debt | $2.0M | $2.1M | $2.2M | $2.4M | $2.5M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Change to shareholder rights
|
Oct 22, 2026 | Oct 21, 2026 |
| 8-K |
Current report
Material agreement
|
Sep 10, 2026 | Sep 9, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 14, 2026 | Aug 14, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 24, 2026 | Jun 24, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
May 15, 2026 | May 15, 2026 |
All 691 PAVmed Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.